In this sense, all the in silicoestimates of SCN9A overexpression with all clinically provenSNP markers of pain in PEPD, SFN, PE and CIP are consistentwith the manifestation of excessive SCN9A in patients withthese pathologies. Here, SCN9A is linked to paroxysmal extreme pain disorder.